The Swiss pharma group has agreed to buy Seattle-based biotech Good Therapeutics and its preclinical-stage PD-1-regulated IL-2 receptor agonist programme for $250 million upfront, with undisclosed ...

The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma ...

a first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein, as monotherapy for the treatment of unresectable locally advanced or metastatic mucosal or acral melanoma who have not ...

PT101 is an engineered IL-2 mutein fused to a protein backbone ... earmarked for the clinical development of PT101 as well as two PD-1 agonist candidates codenamed PT627 and PT001.

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 bispecific antibody fusion protein designed to enhance efficiency while minimizing toxicity.